一例小细胞肺癌患者化疗后骨髓抑制的预防用药分析 |
| |
引用本文: | 徐苏颖,戴助,桂玲. 一例小细胞肺癌患者化疗后骨髓抑制的预防用药分析[J]. 实用药物与临床, 2016, 0(10): 1294-1296. DOI: 10.14053/j.cnki.ppcr.201610022 |
| |
作者姓名: | 徐苏颖 戴助 桂玲 |
| |
作者单位: | 1. 湖北省肿瘤医院药学部,武汉,430079;2. 华中科技大学同济医学院附属同济医院药学部,武汉,430030 |
| |
摘 要: | 目的探讨1例小细胞肺癌患者化疗后骨髓抑制预防用药的指征和使用时机。方法临床药师通过查阅指南和相关文献,充分评估该患者发生粒细胞缺乏伴发热的风险等级,为患者的预防性使用重组人粒细胞集落刺激因子(G-CSF)的时机向医师提出建议,确保患者预防性用药的合理性。结果临床药师判断该患者具有预防性使用G-CSF的指征,建议正确的使用时机应在化疗结束后24~48 h开始。结论临床药师向医师提出合理建议,并提供相应的药学监护,避免患者骨髓功能受到进一步抑制。
|
关 键 词: | 化疗 骨髓抑制 预防性用药 重组人粒细胞集落刺激因子 |
Analysis of prophylactic drug use for a small cell lung cancer patient with myelosup-pression after chemotherapy |
| |
Abstract: | Objective To discuss the indication and timing of prophylactic drug use for a small cell lung canc-er patient with myelosuppression after chemotherapy. Methods Clinical pharmacist evaluated the risk of febrile neutro-penia in the patient and suggested the timing of rational prophylactic G-CSF use,ensuring the safety of treatment. Re-sults The patient was estimated to have the indications for prophylactic G-CSF,and the timing of rational prophylactic G-CSF use was 24 ~48 h after chemotherapy. Conclusion Clinical pharmacists participate in the treatment,provide pharmaceutical care for rational drug use,thus preventing the risk of furthur myelosuppression of the patient. |
| |
Keywords: | Chemotherapy Myelosuppression Prophylactic drug use Recombinant human granulocyte colony stimulating factor |
本文献已被 万方数据 等数据库收录! |
|